Alexandra Gerlach, Associate Editor

The approval makes remestemcel-L-rknd the first approved mesenchymal stromal cell in the United States.

Lerodalcibep is a third-generation PCSK9 inhibitor that demonstrated success in reducing low density lipoprotein cholesterol (LDL-C).

Ultra-processed food consumption fuels the rising rates of childhood obesity, diabetes, and liver disease, highlighting opportunities for pharmacist intervention.

The updated prescribing information recommends laboratory tests prior to prescribing fezolinetant to determine baseline for hepatic function and injury.

The researchers suggest that an imbalance between pro-inflammatory and resolving lipid mediators may drive tumor growth.

The decision is based on positive results from the CAHtalyst trials, which both met their primary and secondary end points.

Emerging research in triple-negative breast cancer highlights the promise of molecular-based approaches to improve treatment outcomes.

Advancements in prevention address cancer risk in high-risk patients and BRCA mutation carriers.

Combining CDK4/6 and PDL-1 inhibitors enhances treatment responses in patients with hormone receptor positive and triple-negative breast cancer.

Novel therapies and personalized treatment plans are improving outcomes for patients with ER-positive breast cancer.

Trastuzumab deruxtecan and trastuzumab emtansine address key challenges such as recurrence and metastases in HER2+ early breast cancer treatment.

At the 2024 San Antonio Breast Cancer Symposium, experts discussed the development, clinical impact, and challenges of antibody-drug conjugates (ADCs).

Experts highlight the importance of dosing and regimen optimization in breast cancer to improve treatment tolerability, reduce toxicities, and improve quality of life for patients.

Experts discuss advancements in hormone receptor–positive/HER2-negative breast cancer treatment while addressing safety, diversity, and fertility challenges.

Navtemadlin has demonstrated meaningful efficacy and safety as a monotherapy or combination treatment in various preclinical and clinical trials.

As experts in medication management and health education, pharmacists can work with the administration to promote effective strategies that reduce misinformation and improve public health outcomes.

Pelabresib is an investigational, oral, small molecule that inhibits bromodomain and extraterminal (BET) proteins.

The data support the use of supportive anemia care agents in combination with ruxolitinib (Jakafi; Incyte Corp).

Zenocutuzumab-zbco is a bispecific antibody that targets and binds to HER2 and HER3.

Metabolic bariatric surgery rates has decreased in response to increased use of glucagon-like peptide-1 (GLP-1) receptor agonists.

Anemia is a very common adverse effect associated with the use of ruxolitinib.

Postural orthostatic tachycardia syndrome (POTS) diagnoses have greatly increased following the COVID-19 pandemic.

E-cigarette manufacturers claim the products aid in smoking cessation for adults without the risk of adolescent usage.

The therapy has similar benefits for both older and younger patients with multiple myeloma.

Lipoprotein(a) is a known risk factor for atherosclerotic cardiovascular disease.

Anemia is a common adverse effect of ruxolitinib, calling for new approaches to mitigate risks.

The addition of navitoclax was associated with durable response and potential disease modification.

Methemoglobinemia is a blood disorder that affects proper release of oxygen around the body.

The proposed rule would increase access to semaglutide for millions of Americans.

Acoramidis is a novel, highly potent transthyretin stabilizer.